JC
Elite in Non-Small Cell Lung Cancer (NCSLC)
Check Dr. Jeffrey M. Clarke's experience treating your condition:
About Dr. Jeffrey M. Clarke

Jeffrey Clarke is an Oncologist in Durham, North Carolina. Clarke has been practicing medicine for over 14 years and is rated as an Elite expert by MediFind in the treatment of Non-Small Cell Lung Cancer (NCSLC). He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NCSLC), Lung Cancer, EGFR Positive Lung Cancer, Squamous Cell Lung Carcinoma, and Orchiectomy. He is licensed to treat patients in North Carolina. Clarke is currently accepting new patients.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 12 clinical trials in the past 15 years. In particular, he has co-authored 18 articles and participated in 9 clinical trials in the study of Non-Small Cell Lung Cancer (NCSLC).

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Jeffrey M. Clarke it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
20 Duke Medicine Cir, Durham, NC 27710
Background & Education
Graduate Institution
Indiana University School Of Medicine, 2008
Specialties
Oncology
Licenses
Student in an Organized Health Care Education/Training Program in NC
Hospital Affiliations
Duke Regional Hospital
Duke University Hospital
Duke Raleigh Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


12 Clinical Trials

A Randomized, Phase II Trial of SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer
A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Paclitaxel in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial) [TOP 1705]
A Phase II Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
View 10 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Elite
Elite
Elite